Knopp Biosciences Broadens Collaboration with NIH to Investigate Eosinophil-Lowering Effects of Dexpramipexole

PITTSBURGH — Knopp Biosciences LLC today announced a second collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to investigate the eosinophil-lowering effects of the investigational drug dexpramipexole.

Execution of the latest Cooperative Research and Development Agreement (CRADA) between Knopp and NIAID follows an agreement announced in January under which NIAID will sponsor a Phase 2 proof-of-concept clinical trial of dexpramipexole in hypereosinophilic syndrome (HES).


Comments are closed.